Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study

A. Goy, S. H. Bernstein, B. S. Kahl, B. Djulbegovic, M. J. Robertson, S. de Vos, E. Epner, A. Krishnan, J. P. Leonard, S. Lonial, S. Nasta, O. A. O'Connor, H. Shi, A. L. Boral, R. I. Fisher

Research output: Contribution to journalArticle

247 Scopus citations

Abstract

Background: We previously reported results of the phase 2, multicenter PINNACLE study, which confirmed the substantial single-agent activity of bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL). Materials and methods: We report updated time-to-event data, in all patients and by response to treatment, after extended follow-up (median 26.4 months). Results: Median time to progression (TTP) was 6.7 months. Median time to next therapy (TTNT) was 7.4 months. Median overall survival (OS) was 23.5 months. In responding patients, median TTP was 12.4 months, median duration of response (DOR) was 9.2 months, median TTNT was 14.3 months, and median OS was 35.4 months. Patients achieving complete response had heterogeneous disease characteristics; among these patients, median TTP and DOR were not reached, and median OS was 36.0 months. One-year survival rate was 69% overall and 91% in responding patients. Median OS from diagnosis was 61.1 months, after median follow-up of 63.7 months. Activity was seen in patients with refractory disease and patients relapsing following high-intensity treatment. Toxicity was generally manageable. Conclusions: Single-agent bortezomib is associated with lengthy responses and notable survival in patients with relapsed or refractory MCL, with considerable TTP and TTNT in responding patients, suggesting substantial clinical benefit.

Original languageEnglish (US)
Pages (from-to)520-525
Number of pages6
JournalAnnals of Oncology
Volume20
Issue number3
DOIs
StatePublished - Mar 11 2009

    Fingerprint

Keywords

  • Bortezomib
  • Mantle cell lymphoma
  • Refractory
  • Relapsed
  • Response
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Goy, A., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., Nasta, S., O'Connor, O. A., Shi, H., Boral, A. L., & Fisher, R. I. (2009). Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Annals of Oncology, 20(3), 520-525. https://doi.org/10.1093/annonc/mdn656